Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines

Table 1 Sensitization of cervical cell lines SiHa and CaSki to ABT-263 by A-1210477 and vice versa

	SiHa		CaSki
A-1210477, μM	*ABT-263* IC₅₀ (μM), fold sensitization by A-1210477
0	10.11 ± 0.34		3.4 ± 0.13
4	2 ± 0.15	5.1***	0.3 ± 0.0013	11.3***
ABT-263, μM	*A-1210477* IC₅₀ (μM), fold sensitization by ABT-263
0	19.85 ± 0.53		7.6 ± 0.11
2			0.9 ± 0.13	8.4****
4	2.58 ± 0.2	7.7***

The IC₅₀ values are doses of drug 1 (bolditalics) that kill 50% of the cells surviving the shown doses of drug 2 (italics). Fold sensitization IC₅₀ drug 1/IC₅₀ drug 2. Errors are SEM, n = 4
Statistically significant differences with the IC₅₀ of drug 1 (bolditalics) are shown as *** p ≤ 0.001 or **** p ≤ 0.0001 determined by two-tailed paired T test. Where the IC₅₀ was not calculable, the lower bound was employed

ISSN: 1756-0500